Policy controversy
Big PharmaAtlas
Health & Medicine · Pharmaceutical industry
Competing accounts of whether drug companies steer the FDA and the medicine people get, versus imperfect but still independent public oversight, without offering treatment guidance.
Open the caseInvolved
document
CHRG-116hhrg35230
event
congressional oversight hearing
program
drug shortage management
person
Elijah Cummings
government agency
European Medicines Agency
concept
industry funding of regulators
program
PDUFA reauthorization
organization
Pharmaceutical industry sponsors
document
Prescription Drug User Fee Act
program
prescription drug user fees
concept
regulatory capture
concept
revolving-door career incentives
organization
The BMJ
organization
U.S. Congress
government agency
U.S. Department of Health and Human Services
government agency
U.S. Food and Drug Administration
government agency
U.S. Government Accountability Office
organization
U.S. House Committee on Oversight and Reform
On the map